AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-42. (Canceled).

43. (New) A method of transporting pharmaceutically active compounds using a liposome comprising a compound of formula (II)



(II)

where:

R_3 is a saturated or unsaturated, straight or branched acyl chain, with 4-26 carbon atoms;

R_4 is a saturated or unsaturated, straight or branched alkyl chain, with 4-26 carbon atoms; and

X^- is the anion of a pharmacologically acceptable acid.

44. (New) The method according to claim 43, in which R_3 is selected from the group consisting of nonanoyl, dodecanoyl, myristoyl, palmitoyl, stearoyl and oleoyl.

45. (New) The method according to claim 43, in which R_4 is selected from the group consisting of nonyl, undecyl, tetradecyl, hexadecyl and oleyl.

46. (New) The method according to claim 45, in which X^- is selected from the group consisting of chloride; bromide; iodide; aspartate; acid aspartate; citrate; acid citrate; tartrate; acid tartrate; phosphate; acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate; acid sulphate; trichloroacetate; trifluoroacetate; methane sulphonate; pamoate and acid pamoate.

47. (New) The method according to claim 43, in which the compound is selected from the group consisting of:

- palmitoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine chloride tetradecyl ester;
- myristoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine bromide hexadecyl ester; and
- oleoyl L-carnitine chloride oleyl ester.

48. (New) The method according to claim 43, in which the pharmaceutically active compound is selected from the group consisting of anticancer, antiangiogenic, antiviral, antibacterial, antifungal, antiprotozaoan agents, compounds active on the cardiovascular system, and immunogenic peptides.

49. (New) The method according to claim 48, in which said pharmaceutically active compound is an anticancer agent or antiangiogenic agent.

50. (New) The method according to claim 49, in which said anticancer agent is selected from the group consisting of taxol and a derivative of camptothecin.

51. (New) The method according to claim 50, in which said derivative of camptothecin is selected from the group consisting of

- 7-benzylooxyiminomethylcamptothecin and

- 7-butoxyiminomethylcamptothecin.

52. (New) The method according to claim 51, in which the liposome additionally contains helper lipids.

53. (New) The method according to claim 52, in which said helper lipid is selected from the group consisting of cholesterol, 1-palmitoyl-2-oleoyl phosphatidyl choline and dioleyl phosphatidyl choline.

54. (New) A method of transporting a cosmetic using a liposome comprising a compound of formula (II)



(II)

where:

R_3 is a saturated or unsaturated, straight or branched acyl chain, with 4-26 carbon atoms;

R_4 is a saturated or unsaturated, straight or branched alkyl chain, with 4-26 carbon atoms; and

X^- is the anion of a cosmetically acceptable acid.

55. (New) The method according to claim 54, in which R_3 is selected from the group consisting of nonanoyl, dodecanoyl, myristoyl, palmitoyl, stearoyl and oleoyl.

56. (New) The method according to claim 54, in which R_4 is selected from the group consisting of nonyl, undecyl, tetradecyl, hexadecyl and oleyl.

57. (New) The method according to claim 56, in which X^- is selected from the group consisting of chloride; bromide; iodide; aspartate; acid aspartate; citrate; acid citrate; tartrate; acid tartrate; phosphate; acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate; acid sulphate; trichloroacetate; trifluoroacetate; methane sulphonate; pamoate and acid pamoate.

58. (New) The method according to claim 54, in which the compound is selected from the group consisting of:

- palmitoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine chloride tetradecyl ester;
- myristoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine bromide hexadecyl ester; and
- oleoyl L-carnitine chloride oleyl ester.

59. (New) The method according to claim 54, in which the liposome additionally contains helper lipids.

60. (New) The method according to claim 59, in which said helper lipid is selected from the group consisting of cholesterol, 1-palmitoyl-2-oleoyl phosphatidyl choline and dioleyl phosphatidyl choline.

61. (New) A composition comprising a liposome comprising a compound of formula (II)



(II)

where:

R_3 is a saturated or unsaturated, straight or branched acyl chain, with 4-26 carbon atoms;

R_4 is a saturated or unsaturated, straight or branched alkyl chain, with 4-26 carbon atoms; and

X^- is the anion of an acid.

62. (New) The composition according to claim 61, in which R_3 is selected from the group consisting of nonanoyl, dodecanoyl, myristoyl, palmitoyl, stearoyl and oleoyl.

63. (New) The composition according to claim 61, in which R_4 is selected from the group consisting of nonyl, undecyl, tetradecyl, hexadecyl and oleyl.

64. (New) The composition according to claim 63, in which X^- is selected from the group consisting of chloride; bromide; iodide; aspartate; acid aspartate; citrate; acid citrate; tartrate;

acid tartrate; phosphate; acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate; acid sulphate; trichloroacetate; trifluoroacetate; methane sulphonate; pamoate and acid pamoate.

65. (New) The composition according to claim 61, in which the compound is selected from the group consisting of:

- palmitoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine chloride tetradecyl ester;
- myristoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine bromide hexadecyl ester; and
- oleoyl L-carnitine chloride oleyl ester.

66. (New) The composition according to claim 61, in which the liposome additionally contains helper lipids.

67. (New) The composition according to claim 66, in which said helper lipid is selected from the group consisting of cholesterol, 1-palmitoyl-2-oleoyl phosphatidyl choline and dioleyl phosphatidyl choline.

68. (New) The composition according to claim 66 in which the liposome comprises a drug or a substance with cosmetic activity.

69. (New) The composition according to claim 68, in which the drug is selected from the group consisting of anticancer, antiangiogenic, antiviral, antibacterial, antifungal, antiprotozoan agents, compounds active on the cardiovascular system, and immunogenic peptides.

70. (New) A composition according to claim 68 comprising a drug which composition is administered orally, parenterally, intravenously, intramuscularly, subcutaneously, transdermally, or in the form of a nasal or mouth spray.